Skip to main content
SpringerLink
Log in

Cytogenetics of Acute Leukemia

  • Chapter
  • First Online:
Book cover Neoplastic Diseases of the Blood

  • 2258 Accesses

Abstract

Cytogenetic abnormalities are an important factor in patient diagnosis, risk assessment, and treatment in acute leukemia. Characteristic genetic abnormalities are recognized as essential for disease classification and are a significant element of the 2008 World Health Organization (WHO) classification (World health organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon, 2008). Some aberrations are involved in the initiation whereas others participate in the progression of different acute leukemias.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. WHO. World health organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  2. Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, Squire JA. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood. 2001;97(11):3581–8.

    Article  CAS  PubMed  Google Scholar 

  3. Gulley ML, Shea TC, Fedoriw Y. Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn. 2010;12(1):3–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a cancer and leukemia group b study. J Clin Oncol. 2001;19(9):2482–92.

    Article  CAS  PubMed  Google Scholar 

  5. Campbell LJ, Oei P, Brookwell R, Shortt J, Eaddy N, Ng A, Chew E, Browett P. Fish detection of pml-rara fusion in ins(15;17) acute promyelocytic leukaemia depends on probe size. Biomed Res Int. 2013;2013:164501.

    PubMed  PubMed Central  Google Scholar 

  6. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cave H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grumayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Moricke A, Schrappe M, Alonso CN, Schafer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R. New insights to the mll recombinome of acute leukemias. Leukemia. 2009;23(8):1490–9.

    Article  CAS  PubMed  Google Scholar 

  7. Eklund EA. Genomic analysis of acute myeloid leukemia: potential for new prognostic indicators. Curr Opin Hematol. 2010;17(2):75–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.

    Article  PubMed  CAS  Google Scholar 

  9. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European leukemianet. Blood. 2010;115(3):453–74.

    Article  PubMed  CAS  Google Scholar 

  10. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung L, Stary J, Zwaan CM, Kaspers GJ, Reinhardt D, A. M. L. C. o. t. I. B. S. Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–205.

    Article  CAS  PubMed  Google Scholar 

  11. Schuback HL, Arceci RJ, Meshinchi S. Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. Semin Hematol. 2013;50(4):325–32.

    Article  CAS  PubMed  Google Scholar 

  12. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Creutzig U, Buchner T, Sauerland MC, Zimmermann M, Reinhardt D, Dohner H, Schlenk RF. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials aml-bfm 93/98 and the adult trials amlcg 92/99 and amlsg hd93/98a. Cancer. 2008;112(3):562–71.

    Article  PubMed  Google Scholar 

  14. Chaudhury SS, Morison JK, Gibson BE, Keeshan K. Insights into cell ontogeny, age, and acute myeloid leukemia. Exp Hematol. 2015;43(9):745–55.

    Article  CAS  PubMed  Google Scholar 

  15. Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, Rubnitz JE, Ribeiro RC, Rytting M, Pui CH, Kantarjian H, Jeha S. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106(11):2495–502.

    Article  PubMed  Google Scholar 

  16. Ortega JJ, Madero L, Martin G, Verdeguer A, Garcia P, Parody R, Fuster J, Molines A, Novo A, Deben G, Rodriguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, Gonzalez JD, Bolufer P, Gonzalez M, Sanz MA. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the pethema group. J Clin Oncol. 2005;23(30):7632–40.

    Article  CAS  PubMed  Google Scholar 

  17. Tallman MS, Altman JK. How i treat acute promyelocytic leukemia. Blood. 2009;114(25):5126–35.

    Article  CAS  PubMed  Google Scholar 

  18. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Dohner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European leukemianet. Blood. 2009;113(9):1875–91.

    Article  CAS  PubMed  Google Scholar 

  19. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF, Australasian L, Lymphoma G. All-trans-retinoic acid, idarubicin, and iv arsenic trioxide as initial therapy in acute promyelocytic leukemia (apml4). Blood. 2012;120(8):1570–80. quiz 1752

    Article  CAS  PubMed  Google Scholar 

  20. Adams J, Nassiri M. Acute promyelocytic leukemia: a review and discussion of variant translocations. Arch Pathol Lab Med. 2015;139(10):1308–13.

    Article  PubMed  Google Scholar 

  21. Grimwade D, Mrozek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol/Oncol Clin N Am. 2011;25(6):1135–61, vii

    Article  Google Scholar 

  22. Won D, Shin SY, Park CJ, Jang S, Chi HS, Lee KH, Lee JO, Seo EJ. Obfc2a/rara: a novel fusion gene in variant acute promyelocytic leukemia. Blood. 2013;121(8):1432–5.

    Article  CAS  PubMed  Google Scholar 

  23. Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q, Xing H, Tian Z, Tang K, Mi Y, Wang B, Wang M, Wang J. Tblr1 fuses to retinoid acid receptor alpha in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia. Blood. 2014;124(6):936–45.

    Article  CAS  PubMed  Google Scholar 

  24. Souza Melo CP, Campos CB, Dutra AP, Neto JC, Fenelon AJ, Neto AH, Carbone EK, Pianovski MA, Ferreira AC, Assumpcao JG. Correlation between flt3-itd status and clinical, cellular and molecular profiles in promyelocytic acute leukemias. Leuk Res. 2015;39(2):131–7.

    Article  CAS  PubMed  Google Scholar 

  25. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22(5):915–31.

    Article  CAS  PubMed  Google Scholar 

  26. Manara E, Bisio V, Masetti R, Beqiri V, Rondelli R, Menna G, Micalizzi C, Santoro N, Locatelli F, Basso G, Pigazzi M. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the aieop aml 2002/01 trial: screening and prognostic impact of c-kit mutations. Leukemia. 2014;28(5):1132–4.

    Article  CAS  PubMed  Google Scholar 

  27. Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmerman M, Creutzig U, Dworzak M, Alonzo T, Johnston D, Hirsch B, Zapotocky M, De Moerloose B, Fynn A, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Forestier E, Salgado C, Balwierz W, Popa A, Rubnitz J, Raimondi S, Gibson B. Clinical impact of additional cytogenetic aberrations, ckit and ras mutations, and treatment elements in pediatric t(8;21)-aml: results from an international retrospective study by the international berlin-frankfurt-munster study group. J Clin Oncol. 2015;33(36):4247–58.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Mrozek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol. 2008;20(6):711–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Basecke J, Cepek L, Mannhalter C, Krauter J, Hildenhagen S, Brittinger G, Trumper L, Griesinger F. Transcription of aml1/eto in bone marrow and cord blood of individuals without acute myelogenous leukemia. Blood. 2002;100(6):2267–8.

    Article  CAS  PubMed  Google Scholar 

  30. Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM, Smith MT, Zhang L, Feusner J, Wiencke J, Pritchard-Jones K, Kempski H, Greaves M. In utero origin of t(8;21) aml1-eto translocations in childhood acute myeloid leukemia. Blood. 2002;99(10):3801–5.

    Article  CAS  PubMed  Google Scholar 

  31. Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E. Frequent asxl2 mutations in acute myeloid leukemia patients with t(8;21)/runx1-runx1t1 chromosomal translocations. Blood. 2014;124(9):1445–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Spath D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Kohne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Gotze K, Horst HA, Ringhoffer M, Lubbert M, Wattad M, Salih HR, Kundgen A, Dohner H, Dohner K. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the german-austrian aml study group (amlsg). Blood. 2013;121(1):170–7.

    Article  CAS  PubMed  Google Scholar 

  33. Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ihle JN, Rowley JD. Consistent intergenic splicing and production of multiple transcripts between aml1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A. 1994;91(9):4004–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Levy ER, Parganas E, Morishita K, Fichelson S, James L, Oscier D, Gisselbrecht S, Ihle JN, Buckle VJ. Dna rearrangements proximal to the evi1 locus associated with the 3q21q26 syndrome. Blood. 1994;83(5):1348–54.

    CAS  PubMed  Google Scholar 

  35. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Lowenberg B, Delwel R. High evi1 levels predict adverse outcome in acute myeloid leukemia: prevalence of evi1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329–37.

    Article  CAS  PubMed  Google Scholar 

  36. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, Haferlach C, Haferlach T. Runx1 mutations are frequent in de novo aml with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8):2348–57.

    Article  CAS  PubMed  Google Scholar 

  37. Luesink M, Hollink IH, van der Velden VH, Knops RH, Boezeman JB, de Haas V, Trka J, Baruchel A, Reinhardt D, van der Reijden BA, van den Heuvel-Eibrink MM, Zwaan CM, Jansen JH. High gata2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Blood. 2012;120(10):2064–75.

    Article  CAS  PubMed  Google Scholar 

  38. Groschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, Bindels EM, Beverloo HB, Dohner H, Lowenberg B, Dohner K, Delwel R, Valk PJ. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of ras/rtk signaling pathways. Blood. 2015;125(1):133–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Lavallee VP, Gendron P, Lemieux S, D’Angelo G, Hebert J, Sauvageau G. Evi1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 2015;125(1):140–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Dohner K, Beverloo HB, Bradner JE, Dohner H, Lowenberg B, Valk PJ, Bindels EM, de Laat W, Delwel R. A single oncogenic enhancer rearrangement causes concomitant evi1 and gata2 deregulation in leukemia. Cell. 2014;157(2):369–81.

    Article  CAS  PubMed  Google Scholar 

  41. Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den Heuvel-Eibrink M, Ussowicz M, De Moerloose B, Catala A, Smith OP, Sedlacek P, Lankester AC, Zecca M, Bordon V, Matthes-Martin S, Abrahamsson J, Kuhl JS, Sykora KW, Albert MH, Przychodzien B, Maciejewski JP, Schwarz S, Gohring G, Schlegelberger B, Cseh A, Noellke P, Yoshimi A, Locatelli F, Baumann I, Strahm B, Niemeyer CM, Ewog MDS. Prevalence, clinical characteristics, and prognosis of gata2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127(11):1387–97.

    Article  CAS  PubMed  Google Scholar 

  42. Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cave H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schafer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Moricke A, Stanulla M, Schrappe M, Sedek L, Szczepanski T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grumayer R, Dingermann T, Klingebiel T, Marschalek R. The mll recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Lavallee VP, Baccelli I, Krosl J, Wilhelm B, Barabe F, Gendron P, Boucher G, Lemieux S, Marinier A, Meloche S, Hebert J, Sauvageau G. The transcriptomic landscape and directed chemical interrogation of mll-rearranged acute myeloid leukemias. Nat Genet. 2015;47(9):1030–7.

    Article  CAS  PubMed  Google Scholar 

  44. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Zwaan CM, V. d. H.-E. MM. Novel prognostic subgroups in childhood 11q23/mll-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Lo NL, Morimoto A, Perot C, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan CM, V. d. H.-E. MM. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/mll-rearranged aml patients: results of an international study. Blood. 2011;117(26):7102–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Shimada A, Taki T, Tabuchi K, Taketani T, Hanada R, Tawa A, Tsuchida M, Horibe K, Tsukimoto I, Hayashi Y. Tandem duplications of mll and flt3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood aml cooperative study group. Pediatr Blood Cancer. 2008;50(2):264–9.

    Article  PubMed  Google Scholar 

  47. Savage NM, Kota V, Manaloor EJ, Kulharya AS, Pierini V, Mecucci C, Ustun C. Acute leukemia with picalm-mllt10 fusion gene: diagnostic and treatment struggle. Cancer Genet Cytogenet. 2010;202(2):129–32.

    Article  CAS  PubMed  Google Scholar 

  48. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R. Prognostic significance of molecular-cytogenetic abnormalities in pediatric t-all is not explained by immunophenotypic differences. Leukemia. 2008;22(1):124–31.

    Article  PubMed  CAS  Google Scholar 

  49. Caudell D, Aplan PD. The role of calm-af10 gene fusion in acute leukemia. Leukemia. 2008;22(4):678–85.

    Article  CAS  PubMed  Google Scholar 

  50. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, Meshinchi S, van den Heuvel-Eibrink MM, Zwaan CM. Nup98/jarid1a is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct hox gene expression pattern. Leukemia. 2013;27(12):2280–8.

    Article  PubMed  CAS  Google Scholar 

  51. Inaba H, Zhou Y, Abla O, Adachi S, Auvrignon A, Beverloo HB, de Bont E, Chang TT, Creutzig U, Dworzak M, Elitzur S, Fynn A, Forestier E, Hasle H, Liang DC, Lee V, Locatelli F, Masetti R, De Moerloose B, Reinhardt D, Rodriguez L, Van Roy N, Shen S, Taga T, Tomizawa D, Yeoh AE, Zimmermann M, Raimondi SC. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood. 2015;126(13):1575–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, Raimondi SC, Downing JR, Razzouk BI, Pui CH, Ribeiro RC. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the st jude aml97 trial. Leukemia. 2009;23(8):1410–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lim G, Choi JR, Kim MJ, Kim SY, Lee HJ, Suh JT, Yoon HJ, Lee J, Lee S, Lee WI, Park TS. Detection of t(3;5) and npm1/mlf1 rearrangement in an elderly patient with acute myeloid leukemia: clinical and laboratory study with review of the literature. Cancer Genet Cytogenet. 2010;199(2):101–9.

    Article  CAS  PubMed  Google Scholar 

  54. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, De Graaf SS, van den BE, Burnett AK, Gibson BE. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials aml 10 and 12. J Clin Oncol. 2010;28(16):2674–81.

    Article  PubMed  Google Scholar 

  55. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA. A retrospective study of 69 patients with t(6;9)(p23;q34) aml emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia. 2006;20(7):1295–7.

    Article  CAS  PubMed  Google Scholar 

  56. Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, Cayuela JM, Chilton L, Fornerod M, de Haas V, Harrison CJ, Inaba H, Kaspers GJ, Liang DC, Locatelli F, Masetti R, Perot C, Raimondi SC, Reinhardt K, Tomizawa D, von Neuhoff N, Zecca M, Zwaan CM, van den Heuvel-Eibrink MM, Hasle H. T(6;9)(p22;q34)/dek-nup214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica. 2014;99(5):865–72.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S. Acute myeloid leukaemia (aml) with t(6;9)(p23;q34) is associated with poor outcome in childhood aml regardless of flt3-itd status: a report from the Children’s Oncology Group. Br J Haematol. 2014;166(2):254–9.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Quelen C, Lippert E, Struski S, Demur C, Soler G, Prade N, Delabesse E, Broccardo C, Dastugue N, Mahon FX, Brousset P. Identification of a transforming myb-gata1 fusion gene in acute basophilic leukemia: a new entity in male infants. Blood. 2011;117(21):5719–22.

    Article  CAS  PubMed  Google Scholar 

  59. Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJ, Locatelli F, Noellke P, Polychronopoulou S, Ravindranath Y, Razzouk B, Reinhardt D, Savva NN, Stark B, Suciu S, Tsukimoto I, Webb DK, Wojcik D, Woods WG, Zimmermann M, Niemeyer CM, Raimondi SC. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007;109(11):4641–7.

    Article  CAS  PubMed  Google Scholar 

  60. Johnston DL, Alonzo TA, Gerbing RB, Hirsch B, Heerema NA, Ravindranath Y, Woods WG, Lange BJ, Gamis AS, Raimondi SC. Outcome of pediatric patients with acute myeloid leukemia (aml) and -5/5q- abnormalities from five pediatric aml treatment protocols: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2013;60(12):2073–8.

    Article  PubMed  Google Scholar 

  61. Gervais C, Murati A, Helias C, Struski S, Eischen A, Lippert E, Tigaud I, Penther D, Bastard C, Mugneret F, Poppe B, Speleman F, Talmant P, VanDen Akker J, Baranger L, Barin C, Luquet I, Nadal N, Nguyen-Khac F, Maarek O, Herens C, Sainty D, Flandrin G, Birnbaum D, Mozziconacci MJ, Lessard M. Acute myeloid leukaemia with 8p11 (myst3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogenetique hematologique. Leukemia. 2008;22(8):1567–75.

    Article  CAS  PubMed  Google Scholar 

  62. Coenen EA, Zwaan CM, Reinhardt D, Harrison CJ, Haas OA, de Hass V, Mihal V, De MB, Jeison M, Rubnitz JE, Tomizawa D, Johnston D, Alonzo TA, Hasle H, Auvrignon A, Dworzak M, Pession A, van der Velden VH, Swansbury J, Wong KF, Terui K, Savasan S, Winstanley M, Vaitkeviciene G, Zimmermann M, Pieters R, van den Heuvel-Eibrink MM. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the international-berlin-frankfurt-munster aml-study group. Blood. 2013;122(15):2704–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, Douer D, Litzow MR, Lazarus HM, Rowe JM, Levine RL, Tallman MS. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res. 2013;37(1):32–6.

    Article  CAS  PubMed  Google Scholar 

  64. Glassman AB, Hayes KJ. Translocation (11;16)(q23;p13) acute myelogenous leukemia and myelodysplastic syndrome. Ann Clin Lab Sci. 2003;33(3):285–8.

    CAS  PubMed  Google Scholar 

  65. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the tp53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539–41.

    Article  CAS  PubMed  Google Scholar 

  67. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lubbert M, Frohling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Dohner K, Dohner H. Tp53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–21.

    Article  PubMed  CAS  Google Scholar 

  68. Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C. Association of the type of 5q loss with complex karyotype, clonal evolution, tp53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer. 2014;53(5):402–10.

    Article  CAS  PubMed  Google Scholar 

  69. Nahi H, Selivanova G, Lehmann S, Mollgard L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C. Mutated and non-mutated tp53 as targets in the treatment of leukaemia. Br J Haematol. 2008;141(4):445–53.

    Article  CAS  PubMed  Google Scholar 

  70. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, Beverloo HB, Sonneveld E, Kaspers GJ, Trka J, Baruchel A, Zimmermann M, Creutzig U, Reinhardt D, Pieters R, Valk PJ, Zwaan CM. Nup98/nsd1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct Hox gene expression pattern. Blood. 2011;118(13):3645–56.

    Article  CAS  PubMed  Google Scholar 

  71. Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. Nup98/nsd1 and flt3/itd coexpression is more prevalent in younger aml patients and leads to induction failure: a cog and swog report. Blood. 2014;124(15):2400–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, Ichikawa H, Tomizawa D, Park MJ, Shimada A, Sotomatsu M, Arakawa H, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y. High prdm16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to flt3-itd, kmt2a-ptd, and nup98-nsd1: the results of the japanese paediatric leukaemia/lymphoma study group aml-05 trial. Br J Haematol. 2016;172(4):581–91.

    Article  CAS  PubMed  Google Scholar 

  73. Gough SM, Slape CI, Aplan PD. Nup98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood. 2011;118(24):6247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Wei S, Wang S, Qiu S, Qi J, Mi Y, Lin D, Zhou C, Liu B, Li W, Wang Y, Wang M, Wang J. Clinical and laboratory studies of 17 patients with acute myeloid leukemia harboring t(7;11)(p15;p15) translocation. Leuk Res. 2013;37(9):1010–5.

    Article  CAS  PubMed  Google Scholar 

  75. Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, de Klein A, Johansson B, Slater R. Fusion of the homeobox gene hlxb9 and the etv6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res. 2001;61(14):5374–7.

    CAS  PubMed  Google Scholar 

  76. Von Bergh AR, van Drunen E, Van Wering ER, van Zutven LJ, Hainmann I, Lonnerholm G, Meijerink JP, Pieters R, Beverloo HB. High incidence of t(7;12)(q36;p13) in infant aml but not in infant all, with a dismal outcome and ectopic expression of hlxb9. Genes Chromosomes Cancer. 2006;45(8):731–9.

    Article  CAS  Google Scholar 

  77. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial aml-bfm 98. J Clin Oncol. 2010;28(16):2682–9.

    Article  CAS  Google Scholar 

  78. Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T. Etv6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012;51(4):328–37.

    Article  CAS  PubMed  Google Scholar 

  79. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M. Etv6 fusion genes in hematological malignancies: a review. Leuk Res. 2012;36(8):945–61.

    Article  PubMed  CAS  Google Scholar 

  80. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Dohner K, Dohner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR. An inv(16)(p13.3q24.3)-encoded cbfa2t3-glis2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22(5):683–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, Casadio R, Pession A, Basso G, Locatelli F. Cbfa2t3-glis2 fusion transcript is a novel common feature in pediatric, cytogenetically normal aml, not restricted to fab m7 subtype. Blood. 2013;121(17):3469–72.

    Article  CAS  PubMed  Google Scholar 

  82. Lavallee VP, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong RN, Sauvageau G, Hebert J. RNA-sequencing analysis of core binding factor aml identifies recurrent zbtb7a mutations and defines runx1-cbfa2t3 fusion signature. Blood. 2016;127(20):2498–501.

    Article  CAS  PubMed  Google Scholar 

  83. Micci F, Thorsen J, Panagopoulos I, Nyquist KB, Zeller B, Tierens A, Heim S. High-throughput sequencing identifies an nfia/cbfa2t3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24). Leukemia. 2013;27(4):980–2.

    Article  CAS  PubMed  Google Scholar 

  84. Abbas S, Sanders MA, Zeilemaker A, Geertsma-Kleinekoort WM, Koenders JE, Kavelaars FG, Abbas ZG, Mahamoud S, Chu IW, Hoogenboezem R, Peeters JK, van Drunen E, van Galen J, Beverloo HB, Lowenberg B, Valk PJ. Integrated genome-wide genotyping and gene expression profiling reveals bcl11b as a putative oncogene in acute myeloid leukemia with 14q32 aberrations. Haematologica. 2014;99(5):848–57.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Torkildsen S, Gorunova L, Beiske K, Tjonnfjord GE, Heim S, Panagopoulos I. Novel zeb2-bcl11b fusion gene identified by rna-sequencing in acute myeloid leukemia with t(2;14)(q22;q32). PLoS One. 2015;10(7):e0132736.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. Blood. 2015;126(8):943–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ. A prospective study of the natural history of transient leukemia (tl) in neonates with down syndrome (ds): Children’s Oncology Group (cog) study pog-9481. Blood. 2006;107(12):4606–13.

    Article  CAS  PubMed  Google Scholar 

  88. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in down syndrome. Blood. 2009;113(12):2619–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO. Increased age at diagnosis has a significantly negative effect on outcome in children with down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891. J Clin Oncol. 2003;21(18):3415–22.

    Article  PubMed  Google Scholar 

  90. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K, Stark B, Harrison CJ, Teigler-Schlegel A, Johansson B. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with down syndrome: an ibfm-sg study. Blood. 2008;111(3):1575–83.

    Article  CAS  PubMed  Google Scholar 

  91. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111(6):2991–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, Kon A, Nagata Y, Sato Y, Wang R, Shiba N, Chiba K, Tanaka H, Hama A, Muramatsu H, Hasegawa D, Nakamura K, Kanegane H, Tsukamoto K, Adachi S, Kawakami K, Kato K, Nishimura R, Izraeli S, Hayashi Y, Miyano S, Kojima S, Ito E, Ogawa S. The landscape of somatic mutations in down syndrome-related myeloid disorders. Nat Genet. 2013;45(11):1293–9.

    Article  CAS  PubMed  Google Scholar 

  93. Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol. 2008;35(4):336–45.

    Article  CAS  PubMed  Google Scholar 

  94. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP. Clinical implications of flt3 mutations in pediatric aml. Blood. 2006;108(12):3654–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109(2):431–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, Skoulakis S, Lillington D, Lister TA, Young BD. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 2005;65(20):9152–4.

    Article  CAS  PubMed  Google Scholar 

  97. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC. The impact of flt3 internal tandem duplication mutant level, number, size, and interaction with npm1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–84.

    Article  CAS  PubMed  Google Scholar 

  98. Bachas C, Schuurhuis GJ, Hollink IH, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ES, Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJ, Cloos J. High-frequency type i/ii mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood. 2010;116(15):2752–8.

    Article  CAS  PubMed  Google Scholar 

  99. Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009;113(5):1002–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–66.

    Article  CAS  PubMed  Google Scholar 

  101. Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B. Aml with mutated npm1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024–32.

    Article  CAS  PubMed  Google Scholar 

  102. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "Prime time"? Blood. 2014;124(23):3345–55.

    Article  CAS  PubMed  Google Scholar 

  103. Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, Tinsley S, Dickson G, Burnett AK, Hills RK, Linch DC. Simpson’s paradox and the impact of different dnmt3a mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072–83.

    Article  CAS  PubMed  Google Scholar 

  104. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S. Prevalence and prognostic implications of cebpa mutations in pediatric acute myeloid leukemia (aml): a report from the Children’s Oncology Group. Blood. 2009;113(26):6558–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double cebpa mutations, but not single cebpa mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Buchner T, Wormann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K. Acute myeloid leukemia with biallelic cebpa gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570–7.

    Article  CAS  PubMed  Google Scholar 

  107. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–18.

    Article  CAS  PubMed  Google Scholar 

  108. Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica. 2008;93(7):976–82.

    Article  PubMed  CAS  Google Scholar 

  109. Frankfurt O, Licht JD, Tallman MS. Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol. 2007;19(6):635–49.

    Article  PubMed  Google Scholar 

  110. Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2006:169–77.

    Google Scholar 

  111. Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, Rizzari C, Rubnitz JE, Smith OP, Sung L, Tomizawa D, van den Heuvel-Eibrink MM, Creutzig U, Kaspers GJ. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33(27):2949–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Third international workshop on chromosomes in leukemia 1980 (1981). Clinical significance of chromosomal abnormalities in acute lymphoblasic leukemia. Cancer Genet Cytogenet. 1981;4:111–37.

    Article  Google Scholar 

  113. Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit YC, Izraeli S, Yeoh AE, Liang DC, Downing JR, Evans WE, Relling MV, Mullighan CG. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of southwest oncology group 9400 study. Blood. 2008;111(5):2563–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG, Lange BJ, Hutchinson RS, Reaman GH, Trigg ME, Arthur DC, Gaynon PS, Uckun FM. Frequency and clinical significance of cytogenetic abnormalities in pediatric t-lineage acute lymphoblastic leukemia: a report from the Children’s Cancer Group. J Clin Oncol. 1998;16(4):1270–8.

    Article  CAS  PubMed  Google Scholar 

  116. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (ukall xii/ecog 2993). Blood. 2009;114(25):5136–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206–14.

    Article  CAS  PubMed  Google Scholar 

  118. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (all): analysis of cytogenetic data from patients treated on the medical research council (mrc) ukallxii/eastern cooperative oncology group (ecog) 2993 trial. Blood. 2007;109(8):3189–97.

    Article  CAS  PubMed  Google Scholar 

  119. Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR, Broadfield ZJ, Harris RL, Taylor KE, Gibson BE, Hann IM, Hill FG, Kinsey SE, Eden TO, Mitchell CD, Harrison CJ. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood. 2003;102(8):2756–62.

    Article  CAS  PubMed  Google Scholar 

  120. Heerema NA, Raimondi SC, Anderson JR, Biegel J, Camitta BM, Cooley LD, Gaynon PS, Hirsch B, Magenis RE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007;46(7):684–93.

    Article  CAS  PubMed  Google Scholar 

  121. Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AJ, Heerema NA. High concordance from independent studies by the Children’s Cancer Group (ccg) and pediatric oncology group (pog) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with nci standard-risk b-precursor acute lymphoblastic leukemia: a Children’s Oncology Group (cog) initiative. Leukemia. 2005;19(5):734–40.

    Article  CAS  PubMed  Google Scholar 

  122. Heerema N, Sensel M, Sather H, Lee M, Hutchinson R, Nachman J, Lange B, Steinherz P, Bostrom B, Gaynon P, Uckun F. Chromosome1 abnormalities in childhood acute lymphoblastic leukemia (all). J Clin Oncol. 2000;19:582a.

    Google Scholar 

  123. Heerema N, Sather H, Reaman G, Hutchinson R, Lange B, Nachman J, Stinherz P, Uckun F, Gaynon P, Trigg M, Arthur D. Cytogenetic studies of acute lymphoblastic leukemia: clinical correlations results from the Children’s Cancer Group. J Assoc Genet Technol. 1998;24:206–12.

    Google Scholar 

  124. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on mrc trial ukall xa. Mrc adult leukaemia working party. Br J Haematol. 1997;96(3):601–10.

    Article  CAS  PubMed  Google Scholar 

  125. Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ, Dastugue N, Schrappe M, Pui CH, Basso G, Silverman LB, Janka-Schaub GE. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110(4):1112–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun F. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 1999;94(12):4036–45.

    CAS  PubMed  Google Scholar 

  127. Harrison CJ, Moorman AV, Broadfield ZJ, Cheung KL, Harris RL, Reza Jalali G, Robinson HM, Barber KE, Richards SM, Mitchell CD, Eden TO, Hann IM, Hill FG, Kinsey SE, Gibson BE, Lilleyman J, Vora A, Goldstone AH, Franklin IM, Durrant J, Martineau M. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol. 2004;125(5):552–9.

    Article  PubMed  Google Scholar 

  128. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CG. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Uckun FM, Pallisgaard N, Hokland P, Navara C, Narla R, Gaynon PS, Sather H, Heerema N. Expression of tel-aml1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42(1-2):41–56.

    Article  CAS  PubMed  Google Scholar 

  130. Burmeister T, Gokbuget N, Schwartz S, Fischer L, Hubert D, Sindram A, Hoelzer D, Thiel E. Clinical features and prognostic implications of tcf3-pbx1 and etv6-runx1 in adult acute lymphoblastic leukemia. Haematologica. 2010;95(2):241–6.

    Article  CAS  PubMed  Google Scholar 

  131. Raynaud SD, Dastugue N, Zoccola D, Shurtleff SA, Mathew S, Raimondi SC. Cytogenetic abnormalities associated with the t(12;21): a collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia. Leukemia. 1999;13(9):1325–30.

    Article  CAS  PubMed  Google Scholar 

  132. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3(9):639–49.

    Article  CAS  PubMed  Google Scholar 

  133. Raimondi SC, Peiper SC, Kitchingman GR, Behm FG, Williams DL, Hancock ML, Mirro J Jr. Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23. Blood. 1989;73(6):1627–34.

    CAS  PubMed  Google Scholar 

  134. Dreyer ZE, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M, Hilden JM, Heerema NA, Sanders JE, McGlennen R, Willman CL, Carroll AJ, Behm F, Smith FO, Woods WG, Godder K, Reaman GH. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and mll gene rearrangements: a report from the Children’s Oncology Group. J Clin Oncol. 2011;29(2):214–22.

    Article  CAS  PubMed  Google Scholar 

  135. Arico M, Camitta B, Scrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui C-H, Masera G, Conter V, Riehm H, Heerema N, Sallan S, Auclerc M-F, Pullen J, Shuster J, Carroll A, Raimondi S, Richards S. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998–1006.

    Article  CAS  PubMed  Google Scholar 

  136. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children’s Oncology Group study. J Clin Oncol. 2009;27(31):5175–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B, C. S. O. Group. Long-term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study aall0031. Leukemia. 2014;28(7):1467–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, Evans WE, Pieters R. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125–34.

    Article  CAS  Google Scholar 

  139. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, Ar K, Wilson CS, Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Downing JR, Relling M, Yang J, Bhojwani D, Carroll WL, Camitta B, Reaman GH, Smith M, Hunger SP, Willman CL. Identification of novel cluster groups in pediatric high-risk b-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116(23):4874–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving J, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab C, Tonnies H, Dyer MJ, Siebert R, Harrison CJ. Deregulated expression of cytokine receptor gene, crlf2, is involved in lymphoid transformation in b-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688–98.

    Article  CAS  PubMed  Google Scholar 

  141. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable kinase-activating lesions in pH-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  143. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G, Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR. Rearrangement of crlf2 in b-progenitor- and down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM, Larsen EC, Mattano LA, Maloney KW, Willman CL, Wood BL, Winick NJ, Carroll WL, Hunger SP, Raetz EA. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk Children’s Oncology Group studies: a report from the Children’s Oncology Group. J Clin Oncol. 2013;31(27):3397–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD, Goulden N, Vora A, Harrison CJ. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the mrc all97/99 and ukall2003 trials. J Clin Oncol. 2013;31(27):3389–96.

    Article  PubMed  Google Scholar 

  146. Penther D, Preudhomme C, Talmant P, Roumier C, Godon A, Mechinaud F, Milpied N, Bataille R, Avet-Loiseau H. Amplification of aml1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with aml1 gene mutation. Leukemia. 2002;16(6):1131–4.

    Article  CAS  PubMed  Google Scholar 

  147. Landau H, Lamanna N. Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep. 2006;1(3):171–9.

    Article  PubMed  Google Scholar 

  148. Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Hutchinson R, Gaynon PS, Arthur DC, Uckun FM. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 1999;94(5):1537–44.

    CAS  PubMed  Google Scholar 

  149. van Zutven LJ, van Drunen E, de Bont JM, Wattel MM, Den Boer ML, Pieters R, Hagemeijer A, Slater RM, Beverloo HB. Cdkn2 deletions have no prognostic value in childhood precursor-b acute lymphoblastic leukaemia. Leukemia. 2005;19(7):1281–4.

    Article  PubMed  CAS  Google Scholar 

  150. Behrendt H, Charrin C, Gibbons B, Harrison CJ, Hawkins JM, Heerema NA, Horschler-Botel B, Huret JL, Lai JL, Lampert F, et al. Dicentric (9;12) in acute lymphocytic leukemia and other hematological malignancies: report from a dic(9;12) study group. Leukemia. 1995;9(1):102–6.

    CAS  PubMed  Google Scholar 

  151. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA. Pax5/etv6 fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia. 2003;17(6):1121–3.

    Article  CAS  PubMed  Google Scholar 

  152. Gastier-Foster JM, Carroll AJ, Ell D, Harvey R, Chen I-M, Ketterling R, Meloni-Ehrig A, Opheim KE, Patil S, Pettenati M, Rao K, Wu S, Heerema NA. Two distinct subsets of dic(9;12)(p12;p11.2) among children with b-cell precursor acute lymphoblastic leukemia (all): Pax5-etv6 and etv6-runx1 rearrangements: a report from the Children’s Oncology Group. ASH Ann Meeting Abstr. 2007;110(11):1439.

    Google Scholar 

  153. Pichler H, Moricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, Konig M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grumayer R, Attarbaschi A. Prognostic relevance of dic(9;20)(p11;q13) in childhood b-cell precursor acute lymphoblastic leukaemia treated with berlin-frankfurt-munster (bfm) protocols containing an intensive induction and post-induction consolidation therapy. Br J Haematol. 2010;

    Google Scholar 

  154. An Q, Wright SL, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Harrison CJ, Strefford JC. Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21. Haematologica. 2009;94(8):1164–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Messinger YH, Higgins R, Devidas M, Hunger SP, Carroll AJ, Heerema NA. Acute lymphoblastic leukemia (all) with t(8;14)(q11.2;q32): B-lineage disease with high proportion of down syndrome. A Children’s Oncology Group (cog) study. ASH Ann Meeting Abstr. 2008;112(11):1477.

    Google Scholar 

  156. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144(2):147–56.

    Article  PubMed  Google Scholar 

  157. Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson R, Nachman JB, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun FM. Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Cancer. 2000;88(8):1945–54.

    Article  CAS  PubMed  Google Scholar 

  158. Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Gaynon PS, Uckun FM. Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Leuk Lymphoma. 2000;36(5–6):467–78.

    Article  CAS  PubMed  Google Scholar 

  159. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia group b experience. Blood. 1999;93(11):3983–93.

    CAS  PubMed  Google Scholar 

  160. Dabaja BS, Faderl S, Thomas D, Cortes J, O’Brien S, Nasr F, Pierce S, Hayes K, Glassman A, Keating M, Kantarjian HM. Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications. Leukemia. 1999;13(6):869–72.

    Article  CAS  PubMed  Google Scholar 

  161. Rao K, Heerema N, Sather H, Sensel M, Lee M, Hutchinson R, Nachman J, Lange B, Steinherz P, Bostrom B, Gaynon P, Uckun F. Deletions of chromosome arm 5q in childhood acute lymphoblastic leukemia (all). Proc Am Soc Clin Oncol. 2000;19:589a.

    Google Scholar 

  162. Heerema NA, Nachman JB, Sather HN, La MK, Hutchinson R, Lange BJ, Bostrom B, Steinherz PG, Gaynon PS, Uckun FM. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children’s Cancer Group. Leukemia. 2004;18(5):939–47.

    Article  CAS  PubMed  Google Scholar 

  163. Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon PS, Uckun FM. Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(22):3837–44.

    Article  CAS  PubMed  Google Scholar 

  164. Gorello P, La Starza R, Varasano E, Chiaretti S, Elia L, Pierini V, Barba G, Brandimarte L, Crescenzi B, Vitale A, Messina M, Grammatico S, Mancini M, Matteucci C, Bardi A, Guarini A, Martelli MF, Foa R, Mecucci C. Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of t-cell acute lymphoblastic leukemia in adults. Haematologica. 2010;95(1):79–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Cauwelier B, Dastugue N, Cools J, Poppe B, Herens C, De Paepe A, Hagemeijer A, Speleman F. Molecular cytogenetic study of 126 unselected t-all cases reveals high incidence of tcrbeta locus rearrangements and putative new t-cell oncogenes. Leukemia. 2006;20(7):1238–44.

    Article  CAS  PubMed  Google Scholar 

  166. Janssen JW, Ludwig WD, Sterry W, Bartram CR. Sil-tal1 deletion in t-cell acute lymphoblastic leukemia. Leukemia. 1993;7(8):1204–10.

    CAS  PubMed  Google Scholar 

  167. Kees UR, Heerema NA, Kumar R, Watt PM, Baker DL, La MK, Uckun FM, Sather HN. Expression of hox11 in childhood t-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children’s Cancer Group (ccg). Leukemia. 2003;17(5):887–93.

    Article  CAS  PubMed  Google Scholar 

  168. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. Activating mutations of notch1 in human t cell acute lymphoblastic leukemia. Science. 2004;306(5694):269–71.

    Article  CAS  PubMed  Google Scholar 

  169. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. Tan-1, the human homolog of the drosophila notch gene, is broken by chromosomal translocations in t lymphoblastic neoplasms. Cell. 1991;66(4):649–61.

    Article  CAS  PubMed  Google Scholar 

  170. Maillard I, Pear WS. Immunology. Keeping a tight leash on notch. Science. 2007;316(5826):840–2.

    Article  CAS  PubMed  Google Scholar 

  171. Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High incidence of notch-1 mutations in adult patients with t-cell acute lymphoblastic leukemia. Leukemia. 2006;20(3):537–9.

    Article  CAS  PubMed  Google Scholar 

  172. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–78.

    Article  CAS  PubMed  Google Scholar 

  173. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M, van den Akker J, Perot C, Pellegrino B, Landman-Parker J, Douay L, Berger R, Bernard OA. Hox11l2 expression defines a clinical subtype of pediatric t-all associated with poor prognosis. Blood. 2002;100(3):991–7.

    Article  CAS  PubMed  Google Scholar 

  174. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, Vermeesch JR, Stul M, Dutta B, Boeckx N, Bosly A, Heimann P, Uyttebroeck A, Mentens N, Somers R, MacLeod RA, Drexler HG, Look AT, Gilliland DG, Michaux L, Vandenberghe P, Wlodarska I, Marynen P, Hagemeijer A. Fusion of nup214 to abl1 on amplified episomes in t-cell acute lymphoblastic leukemia. Nat Genet. 2004;36(10):1084–9.

    Article  CAS  PubMed  Google Scholar 

  175. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human nup214-abl1-positive t cell malignancies. Leukemia. 2008;22(6):1117–24.

    Article  CAS  PubMed  Google Scholar 

  176. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H. Cdkn2a, cdkn2b, and mtap gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2003;37(1):44–57.

    Article  CAS  PubMed  Google Scholar 

  177. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, Pullen J, Bowman WP, Yu AL. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of t-cell acute lymphoblastic leukemia. Clin Cancer Res. 2000;6(4):1219–28.

    CAS  PubMed  Google Scholar 

  178. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric t-cell acute lymphoblastic leukaemia. Br J Haematol. 2008;143(2):153–68.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are unable to include the references for studies by several investigators because of limited space; only the latest references in various topics have been included in this chapter. Special thanks to Heather Breidenbach for assistance with the preparation of the chapter and to Vani Shanker for scientific editing of the chapter.

Author information

Authors and Affiliations

  1. Department of Pathology, The Ohio State University, 1645 Neil Avenue, Columbus, OH, 43210, USA

    Nyla A. Heerema Ph.D., F.A.C.M.G.

  2. Cytogenetics Laboratory, Department of Pathology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA

    Susana Catalina Raimondi Ph.D., F.A.C.M.G.

Authors
  1. Nyla A. Heerema Ph.D., F.A.C.M.G.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susana Catalina Raimondi Ph.D., F.A.C.M.G.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nyla A. Heerema Ph.D., F.A.C.M.G. .

Editor information

Editors and Affiliations

  1. Cancer Research Foundation, Chappaqua, New York, USA

    Peter H. Wiernik

  2. Cancer Research Foundation, Chappaqua, New York, USA

    Janice P. Dutcher

  3. Department of Hematology, Mayo Clinic Department of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Heerema, N.A., Raimondi, S.C. (2018). Cytogenetics of Acute Leukemia. In: Wiernik, P., Dutcher, J., Gertz, M. (eds) Neoplastic Diseases of the Blood. Springer, Cham. https://doi.org/10.1007/978-3-319-64263-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64263-5_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64262-8

  • Online ISBN: 978-3-319-64263-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation